ALK and neuroblastoma: To identify and trace the progression of mechanisms of resistance to lorlatinib, we used the FoundationOne Liquid Assay36 to sequentially profile ctDNA from all patients with ALK-mutated relapsed/refractory neuroblastoma enrolled on the NANT phase 1 clinical trial NCT03107988.